Circassia Pharmaceuticals appoints Jonathan Emms as chief operating officer

07:29 12/08/2019
StockMarketWire.com - Circassia Pharmaceuticals appointed Jonathan Emms to the newly-created role of chief operating officer.

As COO, Emms would further strengthen Circassia's commercial focus and lead the company's global commercial strategy and operational management. He would also join the company's board as an executive director when he joins Circassia on 2 September 2019.

At the same time Circassia's Senior Vice President of R&D, Dr Rod Hafner, would step down from the Board after 11 years as a director, reflecting the company's commercial focus and the approval process for Duaklir and Tudorza's sNDA. He would remain a key member of Circassia's Senior Management Team, however, and continue in his role leading the company's business development, supply chain, medical affairs, regulatory and quality activities.

Jonathan Emms, an established commercial leader, who brought significant senior-level experience of the global pharmaceutical industry to Circassia, the company said. Prior to joining the company, he was chief commercial officer for Pfizer's internal medicines organisation, where he led commercial activities across the company's global operations.



Story provided by StockMarketWire.com

Forex

Commodities

What the Papers Say

telegraph financial times daily mail daily express independent times
21:39 FirstFT: Today’s top stories 
source: FT.com
21:33 PG&E sinks to 7-month low on new wildfire...
source: FT.com
21:30 Wall Street rises for third day while...
source: FT.com
20:09 China social media accounts suspended over...
source: FT.com
19:48 Banking bodies look at shorter trading day...
source: FT.com
19:47 Hong Kong billionaire to buy pub group...
source: FT.com
19:46 Royal Mail accord with workers is...
source: FT.com
19:45 Markets rally despite new Germany...
source: The Guardian
19:20 Saxo chief predicts more fintech takeovers
source: FT.com
19:16 Auction blunder sees sale of oldest...
source: The Daily Mail
[more ...]